FASL antibody (FITC)

Catalog No. ABIN1105947

The FITC-conjugated Hamster Monoclonal anti-FASL antibody (Clone GE 4-90) (ABIN1105947) specifically detects FASL in FACS. The antibody is reactive with Human samples.

Quick Overview for FASL antibody (FITC) (ABIN1105947)

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivity: Human

Host: Hamster

Clonality: Monoclonal

Conjugate: This FASL antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Clone: GE 4-90

Product Details anti-FASL Antibody (FITC)

Specificity: This antibody reacts with Fas Ligand.

Cross-Reactivity (Details): Species reactivity (tested):Human

Purification: Protein A agarose

Immunogen: Recombinant human Fas Ligand

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: PBS, 0.09 % NaN3, 1 % BSA

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2 - 8 °C.

Target Details for FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Alternative Name: CD178 / Fas Ligand

Background: Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that, Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in tern play a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6

Gene ID: 356

NCBI Accession: NP_000630

UniProt: P48023

Pathways: Apoptosis, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity